Last kr116.70 SEK
Change Today +1.40 / 1.21%
Volume 695.6K
MEDAA On Other Exchanges
Symbol
Exchange
OTC US
Stockholm
OTC US
As of 11:29 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

meda ab-a shs (MEDAA) Snapshot

Open
kr115.90
Previous Close
kr115.30
Day High
kr117.40
Day Low
kr115.10
52 Week High
04/25/14 - kr125.17
52 Week Low
02/6/14 - kr74.63
Market Cap
42.7B
Average Volume 10 Days
1.4M
EPS TTM
kr2.98
Shares Outstanding
365.5M
EX-Date
05/8/14
P/E TM
39.2x
Dividend
kr2.41
Dividend Yield
2.06%
Current Stock Chart for MEDA AB-A SHS (MEDAA)

Related News

No related news articles were found.

meda ab-a shs (MEDAA) Related Businessweek News

No Related Businessweek News Found

meda ab-a shs (MEDAA) Details

Meda AB operates as a specialty pharmaceutical company worldwide. It manufactures and sells specialty pharmaceutical products, branded generics, over-the-counter drugs, and other products in various therapy areas, such as respiratory, dermatology, gastroenterology, cardiology, pain and inflammation, and CNS, as well as metabolism/vitamins. The company markets and sells its products through distributors in approximately 120 countries. Meda AB is headquartered in Solna, Sweden.

2,925 Employees
Last Reported Date: 11/14/14

meda ab-a shs (MEDAA) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: kr2.1M
Compensation as of Fiscal Year 2013.

meda ab-a shs (MEDAA) Key Developments

Meda AB Elects Luca Rovati as Board Member and Deputy Chairman

At the extraordinary general meeting (EGM) held on November 6, 2014 of Meda AB (publ), it was resolved that the number of board members of Meda shall be increased by one and amount to nine until the end of the next annual general meeting and elected Luca Rovati, the representative for the shareholder in Meda, Fidim S.r.l., as new board member and Deputy Chairman of Meda.

Meda AB Reports Consolidated Earnings Results for the Third Quarter and Consolidated and Parent Earnings Results for the Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Year 2014

Meda AB reported consolidated earnings results for the third quarter and consolidated and parent earnings results for the nine months ended September 30, 2014. For the quarter, group net sales reached SEK 3,356 million compared to SEK 3,186 million. EBITDA totaled SEK 975 million against SEK 874 million reported last year. Operating profit was SEK 395 million against SEK 322 million reported last year. Profit after tax amounted to SEK 174 million against SEK 147 million reported last year. Earnings per share reached SEK 0.58 against SEK 0.48 reported last year. Profit attributable to parent company shareholders was SEK 174 million against SEK 146 million a year ago. Return on equity was 6.2% against 6.2% a year ago. Cash flow from operating activities was SEK 694 million against SEK 848 million a year ago. For the nine months period net sales of the group reached SEK 10,198 million compared to SEK 9,664 million, corresponding to an increase of 6% and an organic growth1 of 3% compared to previous year. EBITDA amounted to SEK 2,978 million against SEK 2,719 million reported last year. Operating profit totaled SEK 1,283 million against SEK 1,087 million reported last year. Profit after tax amounted to SEK 677 million against SEK 547 million reported last year. Earnings per share reached SEK 2.24 against SEK 1.82 reported last year. Profit attributable to parent company shareholders was SEK 676 million against SEK 551 million a year ago. Net debt as of September 30, 2014 was SEK 14,992 million against SEK 14,734 million as of September 30, 2013. Cash flow from operating activities was SEK 1,991 million against SEK 2,049 million a year ago. On parent basis, for the nine months, the company’s net sales were SEK 4,228 million against SEK 3,980 million a year ago. Operating profit (EBIT) was SEK 577 million against SEK 361 million a year ago. Profit for the period after net financial items (EBT) was SEK 973 million against SEK 734 million a year ago. Net profit was SEK 533 million against SEK 281 million a year ago. The company expects sales for full-year 2014 to reach SEK 15 billion and that the EBITDA margin will improve slightly compared to full-year 2013, excluding integration cost and other cost associated with the Rottapharm transaction. By this, it can see that keep guidance with regard to the net sales and have improved a little bit guidance with regard to the EBITDA.

Meda AB, Q3 2014 Earnings Call, Nov 06, 2014

Meda AB, Q3 2014 Earnings Call, Nov 06, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MEDAA:SS kr116.70 SEK +1.40

MEDAA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.102.00 CHF +1.20
Almirall SA €15.47 EUR +0.05
Ipsen SA €45.10 EUR -0.395
Orion Oyj €29.21 EUR -0.34
Recordati SpA €14.65 EUR +0.35
View Industry Companies
 

Industry Analysis

MEDAA

Industry Average

Valuation MEDAA Industry Range
Price/Earnings 33.0x
Price/Sales 2.3x
Price/Book 2.2x
Price/Cash Flow 39.9x
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDA AB-A SHS, please visit www.meda.se. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.